Crown Bioscience Invests in Commercial Leadership
20.7.2021 15:30:00 EEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe. In this role, Mr Slater will be responsible for the continued growth within the Company’s existing services portfolio and for setting the foundation for the expansion of new services.
The investment in additional leadership within CrownBio’s commercial and strategic development division reflects the increasing breadth and scientific depth of the company's offerings, and an appreciation of the need for tailored solutions at both an account and territory level. The new position will complement recent expansions in CrownBio’s Marketing, Product Management and Scientific Engagement departments, and is part of the company’s broader commitment to ensure that their customers' experience is industry-leading.
Commenting on the appointment, Mike Prosser, Senior Vice President, Commercial and Strategic Development, said, “I am delighted to welcome Alex to the team, and to fill another crucial role for the company, during an exciting phase of CrownBio’s growth. Alex’s extensive leadership experience in the CRO industry, encompassing multiple phases of drug discovery and development, will be invaluable to us as we evolve our teams in line with market opportunity.”
Mr. Slater joins CrownBio from Biocellvia, where he was VP of the business development function. In previous roles, he has served as Global VP for Business Development at Eurofins and held multiple sales leadership positions at Covance/LabCorp.
“During my interview process I was impressed by the strength of the leadership team at CrownBio, their commitment to innovation and the value they place in their customers’ experience,” commented Alex. “Further, the business development team already in place at CrownBio is highly motivated and professional and in my capacity as VP of Business Development I look forward to working with them to accelerate the organization’s future expansion.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Find out more at: http://www.CrownBio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005688/en/
Contact information
Media Enquiries:
Louise Stenson
Crown Bioscience
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 15:36:00 EEST | Press release
Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has already helped more than 26 million travelers through its services, improving customer experience and building loyalty worldwide. Yuvo’s Services - adding value at every stage of the journey
TreviPay Named a Leader in Two 2026 IDC MarketScape Assessments for AI-Enabled A/R Automation and Embedded Payments15.10.2026 15:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced it has been named a Leader in two 2026 IDC MarketScape assessments: the IDC MarketScape: Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise 2026 Vendor Assessment and the IDC MarketScape: Worldwide Embedded Payment Applications in Accounts Receivable Workflows 2026 Vendor Assessment. The recognition comes as enterprise finance teams look beyond automating individual A/R tasks toward coordinating the decisions and actions that drive growth and improve cash flow. We believe these assessments reflect a market in which payment execution, cash application, credit, collections and customer experience are valued when working together in one connected system. The IDC MarketScape for Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise noted the following strengths: Flexible risk retention options: A partnership with Mastercard lets clients offer net terms with
Visa Direct Launches Stablecoin-Powered Money Movement as Pilots Move to Production15.10.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) announced the next phase of its stablecoin strategy as Visa Direct stablecoin capabilities advance from pilot stage to commercial deployment. The milestone marks an important step in bringing stablecoin-enabled money movement into real-world commercial operations. In the initial rollout, Inyo Global, a Visa Direct processor, is the first enabler of this new offering, powering it for eligible Visa Direct clients and partners1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015116414/en/ Over the past year, Visa Direct has worked with clients and partners to explore how stablecoins can help improve the way businesses fund and move money across borders. As interest in faster, more flexible just-in-time funding solutions continues to grow, Visa is now seeing those efforts move beyond experimentation and into day-to-day business operations. As part of this next phase, Visa is working with Inyo Global, a p
Philip Morris International Announces EU Economic Footprint Study 2021-2025: Transformation Made in Europe15.10.2026 14:42:00 EEST | Press release
At a defining moment for Europe’s competitiveness, Philip Morris International Inc. (PMI) (NYSE: PM) today publishes the second edition of its EU Economic Footprint Study, prepared by EY-Parthenon. Spanning 2021 to 2025, the study demonstrates the scale of PMI’s contribution across the European Union and the capabilities developed through its transformation. The company’s footprint reaches far beyond its own operations, supporting suppliers, manufacturers, researchers, retailers, farmers, employees, and communities across Europe. Five key figures from the EU Economic Footprint Study 2021-2025: Nearly €343 billion in total contribution to the EU economy between 2021 and 2025. €22.3 billion in spending with European suppliers and €27.4 billion invested across PMI's European operations, strengthening industrial capacity and supply-chain resilience. €39.5 billion in exports, reinforcing Europe’s position as a manufacturing and export hub. Around 164,000 jobs supported in 2025, including ne
Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application15.10.2026 14:26:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi opened applications for the Future Health Digital Innovation Challenge 2026, welcoming innovators from around the world to develop AI, software, and connected technology solutions that can help people and health systems understand health needs earlier and act sooner. Selected teams will gain access to technical and clinical expertise across Abu Dhabi’s health and innovation ecosystem, alongside structured support to refine their solutions, test assumptions and develop working prototypes, helping them turn promising ideas into real-world impact faster. Selected solutions may also have the opportunity to progress to further validation, incubation, piloting and scale. As part of the programme, three finalists will progress to an awards ceremony at GITEX 2026 and share a total prize pool of USD 105,000. The winning team will receive USD 50,000, and two finalists will receive USD 35,000 and USD 20,000 respectively. Digital technologies are cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom